Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018)
P

Improving MDS Results of Hypomethylating Agents (HMAs): Current Situation, New HMA Schedules and New Drug Combinations

By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Pierre Fenaux
By Society of Hematologic Oncology Sixth Annual Meeting (SOHO 2018) FEATURING Pierre Fenaux
170 views
October 23, 2018
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
12:36
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…

Feat. A. Patel
16:55
Moffitt Cancer Center

Making Sense of the New Classification Systems for MDS in 2024

Feat. R. Komrokji
44:26
University of Colorado Division of Hematology

Novel Therapies in AML and MDS

Feat. D. Pollyea
13:07
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…

Feat. J. Garcia
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
16:50
MDS Foundation

Pre-MDS States: How to Manage CHIP, CCUS and ICUS in the Clinic

Feat. M. Savona
29:20
MyCancerHaven

Experts Discuss Recent Advances in MDS

Feat. R. Vij, M. Sekeres
14:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "IMerge - Results From a Ph3 Study of Imet…

Feat. A. Zeidan
30:34
UChicago Medicine

2023 Updates in AML and MDS

Feat. O. Odenike
14:53
Talha Badar

DDX41 Mutated Germline Predisposition Syndrome-Associated Myeloid Ne…

33:37
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: MDS

Feat. G. Garcia-Manero
16:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Update on CHIP and CCUS

Feat. L. Weeks
07:56
MDS Foundation

Debates in HR-MDS: Cytoreduction Should Precede Allo-HCT

Feat. U. Platzbecker
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray